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TO THE EDITOR
Neurofibromatosis type I (NF1) is one of
the most common autosomal dominant
inherited diseases affecting 1 in 3,500
individuals. It is caused by a germline
mutation in the tumor suppressor gene
NF1 (Viskochil et al., 1990; Wallace
et al., 1990). Hallmarks are the develo-
pment of cafe´ au lait spots and dermal
as well as plexiform neurofibromas
(Riccardi, 1999). Neurofibromas are
heterogeneous tumors composed of
Schwann cells (SCs) in addition to fibro-
blasts, perineurial cells, mast cells, and
lymphocytes (Serra and Rosenbaum,
2000). An additional somatic mutation
in the second copy of the NF1 gene in a
SC population is an essential early step
for neurofibroma formation (Zhu et al.,
2002). In neurofibroma tissues both cells
with biallelic NF1 inactivation ( / )
and those still bearing an intact copy of
the NF1 gene (þ / ) are present (Serra
and Rosenbaum, 2000).
In a suppressive subtractive hybridi-
zation screen comparing mRNA pools
of human neurofibroma derived þ /
and  / SCs, we identified the major
histocompatibility complex (MHC) class
II family to be differentially expressed.
MHCII genes are normally highly
expressed selectively on professional
antigen presenting immune cells
(Krawczyk and Reith, 2006). However,
expression has also been detected in
several solid tumors such as malignant
melanoma and glioma (Tran et al.,
1998; Campoli and Ferrone, 2008).
We generated highly enriched cul-
tures of NF1þ / and NF1 / SCs
from neurofibromas, as well as
NF1þ /þ normal human SCs from per-
ipheral nerves. NF1þ / and NF1 /
SCs were enriched from the same neu-
rofibroma tissue derived from patients
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with NF1. NF1 genotype was monitored
using loss of heterozygosity analysis. In
addition western blot analysis for the
NF1 gene product neurofibromin was
performed. All cultures were set on the
same culture medium for at least 3 days
before expression analysis were per-
formed (see Supplementary Methods).
In western blot analysis MHCII (HLA-
DR, DQ, and DP) expression was strong
in all neurofibromin-deficient NF1 /
SC cultures (10/10) and barely or not
detectable in cultures from NF1þ /
(8/8) and NF1þ /þ SCs (2/2) (Figure 1a).
Neurofibroma-derived fibroblasts and
NF1 / murine embryonal fibroblasts
did not express MHCII (data not shown),
indicating cell type specificity of the
MHCII expressing phenotype. We
examined 20 neurofibromas (15 dermal
and 5 plexiform) of unrelated patients
for HLA-DR, DQ, and DP expression by
immunohistochemistry. We observed a
consistent pattern of expression with a
subpopulation of MHCII-positive spin-
dle cells lying side by side with negative
ones (Figure 1b). To further characterize
the MHCII-positive cells, we used
double and triple immunofluorescence
labeling. S100B served as marker for
SCs. Using triple immunofluorescence
labeling, we could show that MHCII
expression is mainly restricted to
S100B-positive and neurofibromin-
negative SCs, whereby neurofibromin-
positive SCs stained negative for MHCII
(Figure 1c). MHCII expression was also
detectable in lysates from neurofibroma
tissues including dermal and plexiform
variants. RT-PCR analysis of cultured
NF1 / SCs showed expression of
all MHC class II members suggesting
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Figure 1. Upregulation of major histocompatibility complex II (MHCII) in neurofibromin-deficient Schwann cells (SCs) in vitro and in tumor tissue.
(a) Immunoblots of normal human SC culture (SC, þ /þ ) and cultures enriched for NF1þ / and  / SCs from three neurofibromas (ID52, ID98, and ID64).
(b) Immunohistochemistry of neurofibroma shows MHCII expression in a subpopulation of tumor cells (left panel: 100-fold magnification, right panel: 400-fold
magnification; brown areas correspond to antibody binding, nuclei are blue; bar¼10mm). (c) Immunofluorescence of neurofibroma demonstrating inverse
expression of neurofibromin (red) and MHCII (green) in SC (S100B, blue). Bar¼ 10mm. (d), Real-time PCR for class II transactivator (CIITA) and HLA-DRa of a
NF1þ / /  / pair (ID52) along with þ /þ SC. (e) Immunoblots of NF1þ /þ and three different NF1 / neurofibroma SC cultures showing strong
overexpression of HLA-DR in NF1 / SCs. (f) Immunoblots of NF1 / SC after small interfering RNA (siRNA)–mediated knockdown of CIITA demonstrating
decreased levels of MHCII. Data represent six independent experiments with two different cultures.
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involvement of the class II transactivator
(CIITA), known as the master regulator
of MHC class II gene expression
(Krawczyk and Reith, 2006). Consistent
with the dominant role of CIITA in the
regulation of these genes, we found
CIITA mRNA and HLA-DRa mRNA
and protein levels strongly upregulated
in NF1 / SCs (Figure 1d–e). Target-
ing CIITA transcripts with small interfer-
ing RNA (siRNA) results in the down-
regulation of MHCII protein levels,
demonstrating CIITA dependence of
MHCII expression in NF1 / SCs
(Figure 1f).
MHC class II molecules are best
known for their role in antigen presenta-
tion. However, there is evidence from
lymphoid as well as from melanoma
cells that HLA-DR molecules are cap-
able of transducing intracellular signals
after ligand or antibody binding
(Altomonte et al., 1999). Anti-HLA-DR
antibodies have been shown to exert
anti-proliferative and pro-apoptotic
activity on several hematological neo-
plasias in vitro and in vivo (Nagy et al.,
2002). Although an isotype-matched
anti-MHCI (HLA-A,B,C) or non target-
ing isotype control antibody failed to
exert a significant anti-proliferative
effect, anti-MHCII (HLA-DR) antibody
L243 reduced the growth of three dif-
ferent NF1 / SC cultures significan-
tly. Normal human SCs with low-level
HLA-DR expression did not show
reduced cell numbers upon L243
treatment (Figure 2a). Shortening the
assay time from 72 to 24 hours
increased the inhibitory effect of L243
toward NF1 / SCs but not toward
normal human SCs, suggesting a rapid
and transient effect (Figure 2b). Already
after 5 hours of incubation of NF1 /
SCs with L243 the number of living cells
decreased by 20%±3 suggesting the
occurrence of cell death.
Terminal transferase dUTP nick-end
labeling assays performed after 2.5 hours
of treatment confirmed the rapid induc-
tion of apoptotic cell death in L243-
treated NF1 / SCs (Figure 2c).
Furthermore, cell cycle analysis showed
a significant increase of the G2/G1 ratio
in L243-treated cells indicative of a G2
arrest (Figure 2d). siRNA-mediated
knockdown of CIITA itself did not lead
to significant changes in apoptotic rate
or cell cycle distribution but protects
neurofibromin-deficient SCs from anti-
HLA-DR antibody-induced cell death
and G2 arrest (Figure 2e). Of note, the
sensitivity for L243 treatment decreased
in higher passage cells with lower pro-
liferation rate, suggesting that sensitivity
depends on the activation status of the
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Figure 2. Anti-HLA-DR antibody L243 induces apoptosis and G2 arrest in NF1 / SCs. (a) Cell growth upon incubation with L234 (HLA-DR, major
histocompatibility complex II (MHCII)) or W6/32 (HLA-A,B,C, MHCI) antibody of three primary NF1 / SC cultures and normal human SC (þ /þ ). Within
72 hours cell numbers increased 2- to 3-fold in untreated cultures (control); (b) cell growth of NF1 / SCs (ID34) upon incubation with L234 or IgG within
24 hours. (c) Induction of apoptosis was evaluated by flow cytometry determination of terminal transferase dUTP nick-end labeling (TUNEL) staining (2.5 hours).
(d) Cell cycle analysis of NF1 / SCs treated with L243 or IgG control antibody (2.5hours). (e) Small interfering RNA (siRNA)–mediated knockdown of class II
transactivator (CIITA) rescues NF1 / SC from L243-induced apoptosis and G2 arrest. Results are expressed as mean±SD of three independent experiments
(n¼ 3); *Po0.05, **Po0.01 Student’s t-test. NS, nonsignificant.
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cells as shown for lymphoid cells before
(Truman et al., 1994).
Our results show an unexpected
MHCII overexpressing phenotype of
NF1-deficient SCs anticipating further
in depth analysis as it has several
potential important implications. The
phenotype may have a role in the
pathogenesis of neurofibroma through
tumor and immune cell interactions. It
would be interesting to search for
tumor-associated antigens which may
be presented on neurofibroma cells
and could serve as therapeutic targets.
HLA-DR expression itself which induces
pro-apoptotic and anti-proliferative sig-
nals after ligation may be useful for
therapeutic intervention. Given the
abundance of MHCII expression in neu-
rofibromin-deficient SCs targeting of
these tumorigenic cells via cytotoxin-
conjugated antibodies is also an option
for future therapeutic strategies. Further-
more, it will be interesting to evaluate
the potential benefit of a combinatorial
approach of anti-HLA-DR antibodies
with other compounds that have been
shown to be pro-apoptotic and anti-
proliferative in NF1-deficient cells such
as MEK inhibitors (See et al., 2012). In
any case mouse models will be
necessary to further investigate this
unusual phenotype.
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TO THE EDITOR
Primary cutaneous amyloidosis (PCA) is
an itchy skin disorder that is relatively
common in South America and
Southeast Asia (Ollague et al., 1990;
Tan, 1990). The disease is characterized
histologically by focal deposition of
amyloid in the dermal papillae of
lesional skin, but its etiology is un-
known. Although not life-threatening,
the disease affects the patients’ quality
of life severely from uncomfortable
conditions, i.e., itching and undesir-
able appearance. Most PCA cases are
sporadic, but a genetic factor has been
reported to be responsible for the
Abbreviations: IL-31RA, IL-31 receptor A; MCP-1, monocyte chemotactic protein-1; PCA, primary
cutaneous amyloidosis
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MCP-1 as a Key Effector Molecule in FPCA
